Thrombin receptor (TR) activation by a-thrombin requires proteolytic cleavage, although synthetic peptides modeled after the new N-terminus directly effect receptor activation without cleavage, presumably by interacting with an unidentified region of the receptor. To further define critical residues responsible for receptor activation, we performed epitope mapping of anti-TR"lBO, a previously described polyclonal antibody that inhibits peptide ligand-induced receptor activation in various cell types expressing a functional TR.
G PROTEIN-LINKED thrombin receptor (TR) structurally related to other members of the seven-transmembrane receptor family has been identified in endothelial cells,' vascular smooth muscle cells,2 and platelets3-cells activated by thrombin and intimately involved in hemostasis, thrombosis, and atherogenesis. This receptor recapitulates many of the previously identified cellular sequelae of thrombin activation, including phosphoinositide hydrolysis (with accumulation of 3,4-bisphosphate and 3,4,5-trisphosphate), elevation of cytosolic calcium transients ([Ca+2]i), inhibition of adenylyl cyclase, and tyrosine phosphorylation of multiple platelet While its role in platelet activation is well characterized, its precise role in a-thrombin-induced mitogenesis remains inconclusive. In fibroblasts' and vascular smooth muscle cells,8 a-thrombin-induced mitogenic pathway(s) appear to be distinct from those associated with elevations of [Ca+2]i transients. Indeed, responses to a-thrombin in diverse cellular types suggest the presence of multiple activation pathways andor coupling mechani~ms.~"~ This receptor requires proteolytic cleavage by a-thrombin or other proteases for downstream effector-response coupling events3 Accordingly, a model for TR activation has been postulated that incorporates thrombin binding to an acidic hirudin-like domain, proteolytic cleavage of the receptor at Arg4'-Ser42, and subsequent activation by a newly created "tethered ligand."3*" Indeed, synthetic peptides modeled after the new N-terminus directly activate the receptor, irrespective of receptor proteoly~is.~ The molecular interactions between the TR and both the tethered and synthetic peptide ligands have not been defined, however. Previous studies from our laboratory have suggested that the long Nterminal extension of the thrombin receptor (upstream from the first transmembrane domain) may be important in activation-dependent responses to both a-thrombin and synthetic peptide ligands in both platelets and endothelial cells.' This was based on the ability of an antibody (anti-TR"'60) directed against a bacterially expressed segment of the receptor to inhibit peptide ligand-induced cytosolic calcium transients in Chinese hamster ovary (CHO) cells stably expressing a functional TR, endothelial cells, and platelets. We have now ligand-induced platelet aggregation, suggesting that antibodies directed against this region of the TR are important in ligand-mediated activation. Thrombin receptor mutants lacking discrete regions of the TR were subsequently evaluated using microinjected Xenopus oocytes. Whereas a TR mutant lacking amino acid residues ThF-Lys= (TRA67-82) showed normal to exaggerated responses to either a-thrombin or synthetic peptide ligands, only TR mutants with limited deletions spanning the residues GlnsJ-Sersa exhibited dysfunctional responses to either agonist (200 nmol/L athrombin or 200 pmol/L TRU"'). These data provide a model for receptor activation that implicates a discrete and previously uncharacterized sequence within the TR N-terminal extension that is necessary for initiation of signal transduction events independent of the initiating agonist.
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used complementary techniques incorporating epitope scanning of anti-TR1-l6', peptide inhibition, and deletional and in vitro mutagenesis studies to further study molecular determinants of TR activation. We have identified a peptide sequence within the N-terminal extension encompassing amino acid residues Glns3-Ser93 that is required for the initiation of signal transduction events. This region of the receptor is necessary for activation irrespective of the initiating agonist, and identifies a previously uncharacterized regulatory mechanism ultimately specifying activation-dependent responses.
MATERIALS AND METHODS

Reagents.
Purified human a-thrombin (-3,500 U/mg, 1 nmoY L -0.1 U/mL) was supplied by J. Jesty (State University of New York at Stony Brook, Stony Brook, NY). Two peptide ligands representing the new TR N-terminus after thrombin cleavage were used, one of 14 amino acids (TR4'"', SFLLRNPNDKYEPF) and the other of six amino acids SFLLRN), and have been previously described." Preliminary studies demonstrated that both peptides aggregate platelets in a similar manner, with the 6-mer TR"-" being somewhat more potent on a molar basis. Peroxidase-conjugated and fluorescein isothiocyanate (FITQconjugated goat anti-rabbit IgG (heavy-and light chain-specific) were purchased from Jackson Immunolabs (West Grove, PA), and 45Caz+ was purchased from Amersham (Arlington Heights, IL). Oligonucleotide primers used for muta-genesis were synthesized on a single-channel synthesizer (Mode] 381A, Applied Biosystems, Foster City, CA). The production, purification, and cleavage of anti-TR1-Im into F(&'), fragments has been previously described.'
Epifope-mapping studies. TR peptides encompassing the N-termina1 extension after cleavage of the proposed signal peptide and including all three extracellular loops (amino acids 26-99, 161-176, 231-265, and 336-346) were synthesized by t-Boc chemistry onto a solid-phase support covalently coupled to a polypropylene pin (Multi-Pin System, Chiron Mimotopes Pyt. Ltd. Clayton, Australia). A total of 49 overlapping decapeptides, each offset by two amino acids, was synthesized onto pins specifically designed to fit loosely into the wells of a microtiter plate. Polypropylene pins with the covalently coupled peptides were placed in 200 pL of precoat buffer [2% wt/vol bovine serum albumin (BSA), 0.1% Tween 20, phosphate-buffered saline (PBS), pH 7.21 for 60 minutes at 22"C, and washed by gentle agitation in PBS. Anti-TR'"60 IgG diluted to 67 pg/mL was incubated with pins for 70 minutes at 22°C and washed three times with PBS. Pins were then incubated with the peroxidaseconjugated goat anti-rabbit IgG diluted 1:5,000 in STP buffer ( I % sheep serum, 0.1% Tween 20 in 10 mmoVL PBS, pH 7.2) for 60 minutes at 22°C and reacted with a substrate solution containing 0.5 mg/mL ABTS [diammonium 2,2' azino-bis-3-ethylbenzthiazoline 6-sulfonate (Sigma, St. Louis, MO)] and 0.01% wt/vol hydrogen peroxide. Optical densities (OD) of individual wells were read after 5 minutes in an enzyme-linked immunosorbent assay (ELISA) plate reader (Molecular Devices, Menlo Park, CA), and the 490 nm values were subtracted from the 405 nm values to correct for background. To assay for nonspecific antibody binding to the peptides, the assay was repeated using normal rabbit IgG, and the OD values for the normal rabbit IgG were subtracted from those of anti-TR'"".
Platelet aggregation studies. Platelet rich plasma (PRP) from normal human volunteers was prepared by differential centrifugation as previously described'' and adjusted to 3.2 X 10% to 3.9 X IO* platelets per milliliter. For antibody neutralization studies, soluble peptides were synthesized, and equal volumes of peptides and anti-( b )2 or control F(ab'), IgG were incubated for 10 minutes at 22°C and then added to 450 pL PRP for 15 minutes at 22°C. Throughout the experiments, the molar concentrations of the peptides were minimally at a 60-fold molar excess compared with the molar concentration of the antibody.
Immunoaffinity columns containing approximately 38 mg of TR peptide 83-94 (QLPAFISEDASG with an added N-terminal cysteine) or control peptide (QQTNSWPYT-NH,) were prepared with Affigel 15 (Bio-Rad Laboratories, Richmond, CA) at 8.0 mg/mL in 0.1 mom MOPS (3-[N-Morpholino] propanesulfonic acid), pH 7.5 for 2.5 hours at 4°C with coupling efficiencies of approximately 93%. Unreacted groups were blocked with 100 rnmol/L glycine ethyl ester HCI, pH 7.8, for 60 minutes at 4"C, followed by washes in PBS and 0.05 mol/L diethylamine (DEA), pH 11.5. Purified antithrough material was collected. After washing the column in PBS, the bound material was eluted with 0.05 molL DEA, pH 11.5. Both the flow-through and bound material were evaluated for functional activity by platelet aggregometry.
Plasmid constructs and in vitro mutagenesis. The TR cDNA encompassing the open reading frame' was cloned into the BamHI site of M13mp18 for loop-out mutagenesis, using methylation of the mutant strand as the selective process.I3 Oligonucleotide (ON) primers initially designed to loop-out amino acid residues Thrh7-Lys*' (Primer 773) or Glng3-SerQ9 (Primer 774) are as follows: ON 773, S'-AAT GAA AGT GGG TTA CAA C'IT CCT GCA TTC (bp 408-22; bp 471-85, underlined) and ON 774, S'-AGT CCT CTT underlined). Primers were annealed to the single-stranded template TRI-IWJ F a , TR1.160 F(ab'), (-5 mg) was applied to the columns and the flow-CAA AAA TGG CTG ACA CTC m G (bp 455-70; bp 522-37, DNA and second-strand synthesis was completed using T7 DNA polymerase and deoxynucleotide triphosphates (dNTPs), but substituting 5-methyl-dCTP for deoxycytodine triphosphate (dCTP). After ligation, the unmethylated parental strand was nicked with either Msp I or Hae 111, and fully removed with exonuclease 111. The mutated, methylated single-stranded DNA was transformed into the nonrestrictive Escherichia coli host strain SDM, and mutants were identified by direct dideoxy sequence analysis. Once identified, the BamHI insert was isolated from M13 replicative form DNA for ligation into pGEM (Promega, Madison, WI). After plasmid linearization with EcoRI, in vitro transcription was completed using SP6 RNA polymerase (Ambion, Austin, TX), essentially as previously de~cribed.'~ RNA was resuspended in diethyl pyrocarbonate (DEPC)-treated water as the injection vehicle.
Oocyte injections, "Ca2+ measurements, and immunojluorescence. Functional analyses were completed using microinjected Xenopus laevis oocytes and in vitro-transcribed TR cRNA.I4"' 00-cytes were isolated from female frogs anesthesized with 0.2% 3-aminobenzoic acid ethyl ester (tricaine) in dechlorinated tap water, following strict animal handling procedures in compliance with federal and state regulations of the Division of Laboratory and Animal Resources, State University of New York at Stony Brook. Sections of the ovaries were surgically removed, and Dumont stage VNI oocytes were defolliculated by incubation for 2 hours at 25°C with 2 mg/mL type I1 collagenase (Sigma) in modified Barth's solution (MBSH: 82.5 mmol/L NaCl, 2.5 mmoW KCI, 1 mmoVL CaCI,, 1 mmoVL MgCI,, 5 mmoVL HEPES, pH 7.8) without Ca". Oocytes were then washed and incubated overnight at 18°C in the same buffer supplemented with penicillin 100 UlmL and streptomycin 100 @g/ mL. The following day, oocytes were microinjected with individual cRNAs, and subsequently incubated at 18°C in MBSH for 48 hours.
For functional evaluation, oocytes were washed in Ca'+-free MBSH, and pools of 30 oocytes were loaded in the same buffer for 4 hours at 1 8 T with 50 pCi/mL 45Ca'+. Healthy oocytes (seven per well) were transferred to 24-well clusters in 0.5 mL Ca2'-free MBSH and extensively washed in Ca2'-free MBSH to obtain steady-state calcium efflux measurements. After activation by individual agonists, 0.5 mL of solution was removed (and replaced with the same volume) at IO-minute intervals for scintillation counting. The 4sCa2 + release ratio was defined as the counts per minute released during the 10-minute incubation with individual agonists divided by the counts per minute released during the initial steady-state IO-minute interval.
For immunofluorescent staining, microinjected oocytes were fixed in 3% paraformaldehyde in PBS, pH 7.4, for 60 minutes at 4°C and then cryoprotected in graded concentrations of 25% to 75% glycerol. Oocytes were mixed with equal amounts of Aquamount (Lerner, Stamford, CT) and frozen in liquid nitrogen, and 10-pm sections were placed onto slides precoated with 2% gelatin. Sections were blocked for 60 minutes with 5% goat serum at 25T, washed three times with Solution I (154 mmoVL NaCI, 10 mmol/L Tris-HC1, 0.1% BSA, 0.13% sodium azide, pH 8.2), and then incubated with preimmune IgG or anti-TR34-52 I diluted 1:200 in Solution VO. I % goat serum for 16 hours at 4°C. After washing with Solution I, sections were incubated with the FITC-conjugated goat anti-rabbit antibody diluted 1:lOO in Solution VO.1% goat serum. Extensively washed oocytes were mounted in Aquamount, and epifluorescent images were obtained using a Nikon Diaphot inverted microscope equipped with fluorescent optics (Nikon, Garden City, NY). Images were frame-averaged to 256 frames with Image I software (Universal Imaging, Media, PA), using laser light excited at 488 nm and a blocking filter of 500 nm.
RESULTS
Antibodies to the receptor's thrombin cleavage site region or the hirudin-like domain inhibit thrombin-mediated activa- Epitope mapping of anti-TR"'" using a pin peptide ELISA. A total of 49 overlapping decapeptides (each offset by two amino acids) corresponding to predicted TR extracellular sequences (amino acid reridues 2699, 161-176,231-265, and 336-346) was synthesized by t-Boc chemistry onto a solid-phase support covalently coupled to polypropylene pins. Anti-TR"'" I gG diluted to 67 pg/mL was incubated with pins in 96-well microtiter plates for 70 minutes at 22°C. followed by three washes in PBS. Pins were then incubated with the peroxidaseconjugated goat anti-rabbit IgG diluted 1:5,000 for 60 minutes, and reacted with a substrate solution containing 0.5 mg/mL ABTS and 0.01% hydrogen peroxide. OD values of individual wells were read after 5 minutes in an EUSA plate reader. To assess for nonspecific antibody binding to the peptides, the assay was repeated using normal rabbit IgG, and the OD values for the normal rabbit IgG were subtracted from those of anti-TR' "". Individual decapeptides are depicted as horizontal bars, and their specific immunoreactivity (anti-TR"" OD -normal rabbit OD) as the OD, -O D m The epitope profile of anti-TR"" shows four major regions centered between amino acid residues 34-41,48-63,68-75, and 83-90.
tion, but display no inhibitory effects on peptide ligandmediated activation.16." In contrast, we previously showed that a polyclonal antibody (anti-TR"I6O) developed against the N-terminal 160 amino acids of the TR completely eliminated elevations in [Ca+*Ii to either a-thrombin or peptide ligands in C H 0 cells stably expressing the thrombin receptor. This antibody also inhibited increases in [Ca+*Ii in platelets and endothelial cells activated by synthetic peptide ligands, although persistent but qualitatively delayed responses were evident with thrombin activation.' The ability of anti-TR"L60 to inhibit peptide ligand-and a-thrombinmediated receptor activation suggested that a sequence critical for activation-dependent phenomena is contained within the TR N-terminal extension upstream from the first transmembrane domain.
To determine if immunodominant epitopes of anti-TR1-lm existed, and whether they correlated with the functional characteristics of the antibody, epitope mapping of anti-TR"160 was performed using overlapping peptides corresponding to the TR extracellular sequences. Four major peaks of immunoreactivity centered between amino acid residues 34-41, 48-63,68-75, and 83-90 were identified (Fig 1) . As expected, no significant immunoreactivity was identified to any of the peptides representing the extracellular loops, since these regions of the receptor were not contained in the immunizing antigen. Peak 34-41 overlaps the putative thrombin cleavage site3 and peak 48-63 the negatively charged hirudin-like domain." It is unlikely that antibodies to these regions are responsible for the inhibition of peptide ligand-induced receptor activation, however, as previous mutagenesis studies in which these regions were altered or deleted did not demonstrate any effect on peptide ligand-mediated activation event^.^."
To more specifically delineate those residues involved in the antibody's inhibition of peptide ligand-mediated TR activation, soluble peptides were synthesized and tested for their ability to neutralize the inhibitory effect of anti-TR"'60 on peptide ligand-induced platelet aggregation. Whereas peptides encompassing residues 34-52,44-55,65-79, and 87-94 showed no neutralizing activity, peptides spanning residues 83-89, 83-91, 83-94, and 85-99 all neutralized the ability of ant i -TR"' @' to abolish peptide ligand-mediated platelet aggregation (Fig 2A) . Peptides encompassing residues 44-55, 65-79, 83-94, and 87-94 had no inhibitory effect on or control peptide (QQTNSWPYT-NH,) was coupled to Affigel 15; approximately 5.0 mg of anti-TR"'" F(ab'1, was passed over the individual columns, and the flow-through was collected. TRU'"-induced platelet aggregation studies were completed with the starting material, anti-TR"" F(ab'),, and the unbound column flow-through material. Experiments were performed with 0.4 mL of PRP and 0.1 mL of the flowthrough, individually adjusted to antibody concentrations of 300 pg/mL. The anti-TR'"" column flow-through from the peptide 83-94 affinity column showed loss of inhibitory activity comparable to that seen with the peptide neutralization demonstrated in A. The flow-through fraction of the control peptide column (C) displayed no loss of inhibition of peptide-induced platelet aggregation. In C, the now-through from peptide affinity column 83-94 retained its ability to abrogate thrombin-mediated platelet aggregation (final thrombin concentration, 1 nmoll L), confirming that the loss of peptide ligand-mediated inhibtion was unrelated to the affinity chromatography.
peptide-induced platelet aggregation in the absence of antiany inhibitory or activating responses in the absence of the antibody. Passage of anti-TR1-I6' F(ab'), over an affinity column of peptide 83-94 resulted in the selective loss of immunoreactivity with peptides from this region as judged by the ELISA (data not shown). This depleted anti-TR'"60 F(ab'), partially lost its ability to inhibit peptide ligandinduced platelet aggregation (Fig 2B) , essentially similar to the results demonstrable with soluble neutralization studies. To exclude the possibility that the elution conditions altered the functional characteristics of anti-TR'"", the antibody was incubated with DEA, pH l 1 S , and neutralized; this did not reduce the antibody's inhibitory activity against peptideinduced platelet aggregation (data not shown). Additionally, this depleted anti-TR'"60 F(ab'), maintained its ability to inhibit thrombin-induced platelet aggregation (Fig 2C) , as expected, because of the retention of antibodies to the thrombin cleavage site and hirudin-like domains.'.'' In contrast, passing anti-TR'"" F(ab'), over an affinity column of a control peptide (QQTNSWPYT) did not lead to loss of inhibitory activity (Fig 2B) .
These results suggested that (1) distinct immunoreactive epitopes were present within the anti-TR"Im antibody, and (2) a small region within the distal portion of the N-terminal TRl-160 (data not shown). None of the peptides displayed extension may be important in the receptor activation mechanism, most likely in cooperative interactions with other regions. Confirmation of these observations was subsequently pursued by functional evaluation of thrombin receptor mutants in microinjected X luevis oocytes. As demonstrated in Fig 3A, thrombin-treated microinjected oocytes showed a rapid elevation of CaZ+ release when injected with 5 ng of TR cRNA, but not with water alone. Injection of a greater quantity (25 ng) of cRNA resulted in a higher peak Ca2+ release. Similar results were evident when oocytes were activated by the synthetic peptide ligand (Fig 3B) , and again no release was seen with water-injected controls. Based on the functional studies with anti-TR"I6', two TR deletional mutants immediately contiguous to each other were generated: one lacked amino acid residues Thr67-Lysx2 (TRA67-82), and the other lacked residues (TRA83-99). AS shown in Fig  4, oocytes microinjected with TRA67-82 cRNA responded normally to both a-thrombin and TR42-55. In sharp contrast, however, oocytes microinjected with TRA83-99 cRNA displayed no responses to either agonist. Dose-response curves were then completed using progressively higher concentrations of both agonists (Fig 5) . Again, no responses were evident with oocytes microinjected with TRA83-99 cRNA, even when activated by much higher concentrations of either a-thrombin or TR42-47. Oocytes microin- jected with TRA67-82 cRNA, however, displayed rapid activation-dependent responses to both agonists, and these responses were more pronounced than those of oocytes microinjected with wild-type TR cRNA ( P < .05 for activation by 100 nmolL a-thrombin only). It is improbable that the unresponsiveness evident with TRA83-99 is related simply to a shortening of the N-terminal extension, as a deletional mutant immediately contiguous to this region (TRA67-82) remained completely functional; furthermore, others have shown that TR mutants lacking 13 amino acids of the hiru- din-like domain also display normal responses to synthetic peptide ligands."
To ensure that both TR mutants were expressed on the cell-surface membrane, we performed immunofluorescence staining of microinjected oocytes using an antibody directed against a synthetic peptide encompassing the thrombin cleavage site (a~~ti-TR'~-'~).l As shown in Fig 6, epifluorescent images identified similar patterns of staining with oocytes expressing either mutant. In both cases cell-surface expression was similar in intensity to that seen with oocytes microinjected with wild-type TR (data not shown), and was limited in its distribution to the oocyte animal pole, consistent with previous observations.'* No staining was evident using preimmune control IgG or with uninjected oocytes stained with anti-TR"4-5*.
The region encompassing TR residues Gln83-Ser99 was subsequently evaluated more extensively by deletional and in vitro mutagenesis studies. The TR mutant lacking six amino acids immediately contiguous to the predicted membrane insertion site showed essentially normal responses when compared with wild-type microinjected TR (Fig 7) . In sharp contrast, however, neither of two small deletional mutants (GlnS3-Iles8 and SeP9-Ser9') spanning TR amino acid residues Glns3-Ser93 responded to either agonist. Previous reports had demonstrated the importance of the positively charged N-terminus in activation by synthetic peptide ligands,'* suggesting that receptor activation may be affected by interaction with a negatively charged residue. Accordingly, mutagenesis studies were completed on Glum and Asp". Single alanine substitutions at either of these sites did not reproduce the previously identified effects, however, excluding the possibility that the functional properties within this region of the TR are solely mediated by the charge characteristics of these amino acid residues.
DISCUSSION
The TR is unusual among G protein-coupled receptors in that thrombin-mediated proteolysis appears to be a sine qua For personal use only. on October 26, 2017. by guest www.bloodjournal.org From non for activation. The subsequent self-activation process involving the generation of a neoligand is also unique. Structural determinants of synthetic TR peptide analogs have been extensively studied(',''.'"."' and consistently demonstrate (1) the importance of the N-terminus in receptor activation and (2) the need for a minimal penta-or hexapeptide "core" sequence for inducing activation. What remains unknown, however, is the region(s) on the body of the receptor with which the peptide ligand interacts (binding site) and the mechanism of ligand-mediated receptor activation. Previous work in this laboratory using anti-TR'"'" had suggested that the N-terminal extension may be structurally involved in peptide ligand-associated receptor activation phenomenon.' The molecular mechanism(s) of this effect remained incompletely characterized, however.
Using epitope scanning and functional antibody neutralization studies, regulatory determinants of TR activation were initially studied. Anti-TR"'" antibodies consistently abrogated ligand-induced platelet aggregation, while peptide neutralization or selective removal of a subset of antibodies directed at the region encompassing-and inclusive ofresidues Proxs-SerXp neutralized this inhibitory effect. This suggested that the subset of antibodies to this defined region were important in the antibody's inhibitory effects. Such studies cannot, however, differentiate between direct steric effects of such antibodies and/or allosteric effects operating at a distance.
To further study this region of the receptor, mutagenesis studies were subsequently studied using microinjected Xenopus oocytes. Only TR mutants encompassing the region previously defined by antibody neutralization studies did not respond to either agonist. To exclude the possibility that molecular perturbations contiguous to the membrane insertion site nonspecifically affected the functional integrity of the receptor, we generated a TR mutant lacking the hexapeptide sequence immediately adjacent to the first transmembrane domain. This mutant (Gly"J-Sei'J) showed normal function, lending additional support for the specificity of the observations collectively made with previous mutagenesis studies. Whereas steric effects may have explained the initial inhibitory effects of the antibody, this is not consistent with the mutagenesis data, which establish that this region plays a functional role in the initiation of signal transduction effects. Surprisingly, the TR mutant TRA67-82 showed enhanced responses when compared with wild-type TR. These responses were evident upon activation with either a-thrombin or synthetic peptide ligand and suggest that this portion of the receptor may have modulating effects on activation phenomena. Potential mechanisms for this observation could include steric effects regulating the availability of the tethered ligand for its recognition sequence or direct modulation of ligand affinity for its interactive domain. These observations raise the possibility, therefore, that an additional mechanism regulating receptor activation is operational within this region of the receptor. Mutagenesis studies within the TR region Glnm-SerB. TR deletional mutants lacking residues Gln''-lle" (TRA83-88), S e pSer" (TRA89-931, Gly9'-Ser9 (TRA94-991, or single alanine substitutions at Glum and Asp" were generated by site-directed mutagenesis as outlined in Materials and Methods. Individual cRNAs (25 ng) were microinjected into Xenopus oocytes for functional measurements, essentially as outlined in the Fig 3 legend , and maximal "Ca*' release was quantitated at 10 minutes after activation by 10 nmol/L a-thrombin or 50 pmol/L TR' *"' . Data are expressed as the percent maximal response relative t o oocytes microinjected with 25 ng wild-type TR cRNA, and represent the mean of six individual wells from three distinct series of experiments.
For personal use only. on October 26, 2017. by guest www.bloodjournal.org From By analogy to the prototypic seven-transmembrane proteins rhodopsin and the &adrenergic receptor, the ligandbinding site frequently involves residues within the transmembrane helices." However, the TR lacks the crucial aspartic acid residue in the third transmembrane domain that has been implicated in bridging the positively charged amine moiety of catecholamines to the &adrenergic receptor." Recently, molecular genetic studies of the recently cloned seven-transmembrane calcium-sensing receptor identified mutations in the N-terminal extension as contributing to the decrease in calcium binding.23 This affords a precedent for considering the N-terminus as a potential ligand-binding site. Alanine mutagenesis substitutions of both acidic residues within the TR region Gln83-Ser93 did not demonstrate any effect on receptor activation. Thus, this argues against a simple model in which the positively charged N-terminus of the peptide ligand interacts with one of these negatively charged amino acid residues.
Complementary techniques using functional platelet neutralization and mutagenesis studies implicate the region Glns3-Ser9' near the first transmembrane domain as being necessary for activation-dependent responses independent of the initiating agonist. Whereas our data support the role of this discrete region within the TR N-terminal extension as being necessary for receptor activation, the molecular mechanisms of this effect remain poorly characterized. This region may represent the binding site for the peptide ligand or indirectly affect peptide-ligand binding. Alternatively, this peptide sequence may interact with other transmembrane regions, or effect receptor phosphorylation, signaling mechanisms, etc, via critical conformational adjustments. Despite these unresolved issues, these data provide additional evidence for the complexity of thrombin receptor activation by defining a previously uncharacterized regulatory mechanism ultimately specifying receptor activation phenomena. The role of this sequence in receptor-coupling mechanisms, and in the regulation of TR activatioddesensitization phenomenon is currently being addressed, and may further elucidate regulatory mechanisms controlling TR cell signaling events to either a-thrombin or peptide ligand analogs.
NOTE ADDED IN PROOF
Since the submission of this report, another group studying mechanisms of thrombin receptor activation has reported results consistent with those in this report," and in agreement with our original observations on the importance of the Nterminal extension in ligand-mediated activation. By creating a series of Xenopuskuman TR chimeras and studying ligandmediated receptor activation, Gerstzen et aIz4 concluded that the N-terminal extension and the second extracellular loop defined regions important for receptor activation. Indeed, TR residues encompassing amino acids 76-93 alone appeared especially important for receptor activation. Our results are entirely consistent with and further extend these observations, defining the critical domains to amino acid residues 83-93. Despite both these reports, however, direct interaction of the ligand with this region of the receptor has not been demonstrated, and the molecular mechanism(s) whereby synthetic peptide ligands interact with the receptor to effect cell-signaling events remain incompletely characterized.
